BridgeBio price target raised to $50 from $45 at Evercore ISI
Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares ...
FiercePharma1d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Here are the year’s losing stocks that could see a big rebound in early 2025
Tax-loss selling candidates such as Nike, could surprise investors with big gains in 2025, say Evercore strategists.
Evercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) on December 20 and set a ...
bovnews3d
Unum Group (UNM) Stock: A Deeper Look at Its True Potential
Unum Group (UNM) stock saw a modest uptick, ending the day at $72.01 which represents a slight increase of $1.05 or 1.48% from the prior close of $70.96. The stock opened at $70.95 and touched a low ...
This Evercore Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Keefe, Bruyette & Woods analyst Aidan Hall upgraded the rating for Evercore Inc. EVR from Market Perform to Outperform and ...
Fintel on MSN4d
Evercore ISI Group Downgrades Spero Therapeutics (SPRO)
Fintel reports that on December 20, 2024, Evercore ISI Group downgraded their outlook for Spero Therapeutics (NasdaqGS:SPRO) ...
Fintel on MSN4d
Keefe, Bruyette & Woods Upgrades Evercore (EVR)
Fintel reports that on December 20, 2024, Keefe, Bruyette & Woods upgraded their outlook for Evercore (NYSE:EVR) from Market ...
Breaking Down Evercore: 5 Analysts Share Their Views
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $307.2, a high ...
Evercore upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette upgraded Evercore (EVR) to Outperform from Market Perform with a price target of $339, up from $269. The firm says that despite ...
The Motley Fool4d
Should You Buy ChargePoint Stock While It's Below $4?
ChargePoint's stock has plunged since its SPAC-backed debut. It faces tough macro and competitive headwinds. It could trade at a discount valuation for the foreseeable future. But today, it trades at ...
MMO Bomb4d
The came will expand to larger testing, increased testing frequency, and an early access launch.
It's been a bit of an odd year for Evercore Heroes: Ascension. To catch you up, the game entered 2024 as kind of a mash-up ...